Developing the Corporate CMC Regulatory Compliance Strategy

  • John Geigert

Abstract

‘We have to move fast because the competition is on our tail; we have limited funds and staff to move our biopharmaceutical through clinical development so we cannot do everything and hire everybody we want; so what CMC must we absolutely have to do now to be successful, and what can we do at a later stage of clinical development?’

Keywords

Toxicity Sucrose Fermentation Europe Assure 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • John Geigert
    • 1
  1. 1.BioPharmaceutical Quality SolutionsCarlsbadUSA

Personalised recommendations